Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Riverside Methodist Hospital
mi
from
Columbus, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Grant Medical Center
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Grant Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Southern Ohio Medical Center
mi
from
Portsmouth, OH
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of Oklahoma Health Sciences Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Sentara Cancer Institute at Sentara CarePlex Hospital
mi
from
Hampton, VA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Sentara Cancer Institute at Sentara CarePlex Hospital
mi
from
Hampton, VA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Sentara Leigh Hospital
mi
from
Norfolk, VA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Sentara Leigh Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Sentara Hospitals
mi
from
Norfolk, VA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Sentara Hospitals
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
University of California at San Francisco
mi
from
San Francisco, CA
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Scottsdale Healthcare Hospitals DBA HonorHealth
mi
from
Scottsdale, AZ
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Scottsdale Healthcare Hospitals DBA HonorHealth
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
University of Michigan Health System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  2/27/2018
British Columbia Cancer Agency - Vancouver Centre
mi
from
Vancouver,
Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1/2 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral EPI-506 in Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 2/27/2018
British Columbia Cancer Agency - Vancouver Centre
mi
from
Vancouver,
Click here to add this to my saved trials
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas
Status: Enrolling
Updated:  2/27/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
A Phase II Clinical Trial of Angiotensin 1-7 For the Second or Third Line Treatment of Patients With Metastatic or Unresectable Sarcomas
Status: Enrolling
Updated: 2/27/2018
Wake Forest University Health Sciences
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy
Status: Enrolling
Updated:  2/27/2018
Ctrc @ Uthscsa
mi
from
San Antonio, TX
A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer
A Phase II Trial of Intravenous Ontak to Treat Epithelial Ovarian Cancer FIGO Stage III or Stage IV, or Extraovarian Peritoneal Carcinoma, of Fallopian Tube Carcinoma Failing or Ineligible for First-Line Therapy
Status: Enrolling
Updated: 2/27/2018
Ctrc @ Uthscsa
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  2/27/2018
Clinical Research Facility
mi
from
Duarte, CA
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 2/27/2018
Clinical Research Facility
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  2/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 2/27/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  2/27/2018
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 2/27/2018
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated:  2/27/2018
Clinical Research Facility
mi
from
Nashville, TN
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Status: Enrolling
Updated: 2/27/2018
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Allegheny General Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Baystate Health
mi
from
Springfield, MA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Baystate Health
mi
from
Springfield, MA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Beaumont Health System
mi
from
Royal Oak, MI
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Beaumont Health System
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Carolinas HealthCare System
mi
from
Charlotte, NC
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Carolinas HealthCare System
mi
from
Charlotte, NC
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Charleston Research Institute
mi
from
Charleston, NC
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Charleston Research Institute
mi
from
Charleston, NC
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Cleveland Clinic
mi
from
Cleveland, OH
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Fred Hutchinson Cancer Research Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Geisinger Medical Center
mi
from
Danville, PA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Georgia Lung Associates, PC
mi
from
Austell, GA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Georgia Lung Associates, PC
mi
from
Austell, GA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Henry Ford Hospital
mi
from
Detroit, MI
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Inova Healthcare
mi
from
Fairfax, VA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Inova Healthcare
mi
from
Fairfax, VA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Johns Hopkins Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Kentuckiana Pulmonary Associates
mi
from
Louisville, KY
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
LeBaurer Healthcare
mi
from
Greensboro, NC
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
LeBaurer Healthcare
mi
from
Greensboro, NC
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Medical University of South Carolina
mi
from
Charleston, SC
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
New York University Clinical Cancer Center
mi
from
New York, NY
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
New York University Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Oregon Clinic
mi
from
Portland, OR
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Oregon Clinic
mi
from
Portland, OR
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Pulmonary & Crit Care Associates of Baltimore
mi
from
Baltimore, MD
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Pulmonary & Crit Care Associates of Baltimore
mi
from
Baltimore, MD
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Pulmonary Associates of Southern Arizona
mi
from
Tucson, AZ
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Pulmonary Associates of Southern Arizona
mi
from
Tucson, AZ
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Salem Chest Specialists
mi
from
Winston-Salem, NC
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Salem Chest Specialists
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Sarasota Memorial Hospital
mi
from
Sarasota, FL
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Scott & White Clinic
mi
from
Temple, TX
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Scott & White Clinic
mi
from
Temple, TX
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
St. Joseph's Hospital and Medical Center
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
St. Luke's Medical Center
mi
from
Chesterfield, MO
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
St. Luke's Medical Center
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Suburban Lung Associates
mi
from
Elk Grove Village, IL
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Suburban Lung Associates
mi
from
Elk Grove Village, IL
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
University of Southern California
mi
from
Los Angeles, CA
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated:  2/28/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Early Diagnosis of Pulmonary Nodules
Early Diagnosis of Pulmonary Nodules Using A Plasma Proteomic Classifier, Protocol Number 1001-12
Status: Enrolling
Updated: 2/28/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials